TY - JOUR
T1 - Immunohistochemistry of pulmonary biomarkers a perspective from members of the pulmonary pathology society
AU - Thunnissen, Erik
AU - Allen, Timothy Craig
AU - Adam, Julien
AU - Aisner, Dara L.
AU - Beasley, Mary Beth
AU - Borczuk, Alain C.
AU - Cagle, Philip T.
AU - Capelozzi, Vera Luiza
AU - Cooper, Wendy
AU - Hariri, Lida P.
AU - Kern, Izidor
AU - Lantuejoul, Sylvie
AU - Miller, Ross
AU - Mino-Kenudson, Mari
AU - Radonic, Teodora
AU - Raparia, Kirtee
AU - Rekhtman, Natasha
AU - Roy-Chowdhuri, Sinchita
AU - Russell, Prudence
AU - Schneider, Frank
AU - Sholl, Lynette M.
AU - Tsao, Ming Sound
AU - Vivero, Marina
AU - Yatabe, Yasushi
PY - 2018
Y1 - 2018
N2 - The use of immunohistochemistry for the determination of pulmonary carcinoma biomarkers is a well-established and powerful technique. Immunohistochemisty is readily available in pathology laboratories, is relatively easy to perform and assess, can provide clinically meaningful results very quickly, and is relatively inexpensive. Pulmonary predictive biomarkers provide results essential for timely and accurate therapeutic decision making; for patients with metastatic non-small cell lung cancer, predictive immunohistochemistry includes ALK and programmed death ligand-1 (PD-L1) (ROS1, EGFR in Europe) testing. Handling along proper methodologic lines is needed to ensure patients receive the most accurate and representative test outcomes.
AB - The use of immunohistochemistry for the determination of pulmonary carcinoma biomarkers is a well-established and powerful technique. Immunohistochemisty is readily available in pathology laboratories, is relatively easy to perform and assess, can provide clinically meaningful results very quickly, and is relatively inexpensive. Pulmonary predictive biomarkers provide results essential for timely and accurate therapeutic decision making; for patients with metastatic non-small cell lung cancer, predictive immunohistochemistry includes ALK and programmed death ligand-1 (PD-L1) (ROS1, EGFR in Europe) testing. Handling along proper methodologic lines is needed to ensure patients receive the most accurate and representative test outcomes.
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85042635867&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/28686497
U2 - https://doi.org/10.5858/arpa.2017-0106-SA
DO - https://doi.org/10.5858/arpa.2017-0106-SA
M3 - Review article
C2 - 28686497
SN - 0003-9985
VL - 142
SP - 408
EP - 419
JO - Archives of Pathology & Laboratory Medicine
JF - Archives of Pathology & Laboratory Medicine
IS - 3
ER -